An in vitro model of Parkinson's disease: Linking mitochondrial impairment to altered α-synuclein metabolism and oxidative damage

Journal of Neuroscience

Volumn 22, Issue 16, 2002, Pages 7006-7015

  Sherer, Todd B ^a   Betarbet, Ranjita ^a   Stout, Amy K ^a   Lund, Serena ^a   Baptista, Melisa ^b   Panov, Alexander V ^a   Cookson, Mark R ^b   Greenamyre, J Timothy ^a,c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

Carbonyls; Caspase 3; Cytochrome c; Glutathione; Ubiquitin; synuclein

Indexed keywords

ALPHA SYNUCLEIN; CASPASE 3; CYTOCHROME C; GLUTATHIONE; ROTENONE; UBIQUITIN;

APOPTOSIS; ARTICLE; BRAIN MITOCHONDRION; CELL GROWTH; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; LATENT PERIOD; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN METABOLISM; STRIATONIGRAL DEGENERATION;

EID: 0037104723     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.22-16-07006.2002     Document Type: Article

References (62)

1. Alam ZI, Daniel SE, Lees AJ, Marsden DC, Jenner P, Halliwell B (1997) A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J Neurochem 69:1326-1329.
2. Bailey SM, Pietsch EC, Cunningham CC (1999) Ethanol stimulates the production of reactive oxygen species at mitochondrial complexes I and III. Free Radic Biol Med 27:891-900.
3. Barrientos A, Moraes CT (1999) Titrating the effects of mitochondrial complex I impairment in the cell physiology. J Biol Chem 274:16188-16197.
4. Bennett MC, Bishop JF, Leng Y, Chock PB, Chase TN, Mouradian MM (1999) Degradation of a-synuclein by proteasome. J Biol Chem 274:33855-33858.
5. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3:1301-1306.
6. Boldyrev AA, Carpenter DO, Huentelman MJ, Peters CM, Johnson P (1999) Sources of reactive oxygen species production in excitotoxin-stimulated cerebellar granule cells. Biochem Biophys Res Commun 256:320-324.
7. Burke RE, Kholodilov NG (1998) Programmed cell death: Does it play a role in Parkinson's disease? Ann Neurol 44:S126-S133.
8. Cassarino DS, Fall CP, Swerdlow RH, Smith TS, Halvorsen EM, Miller SW, Parks JP, Parker Jr WD, Bennett Jr JP (1997) Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. Biochim Biophys Acta 1362:77-86.
9. Chinopoulos C, Adam-Vizi V (2001) Mitochondria deficient in complex I activity are depolarized by hydrogen peroxide in nerve terminals: Relevance to Parkinson's disease. J Neurochem 76:302-306.
10. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, Marsden CD (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 52:381-389.
11. Dumont A, Hehner SP, Hofmann TG, Ueffing M, Droge W, Schmitz ML (1999) Hydrogen peroxide-induced apoptosis is CD95-independent, requires the release of mitochondria-derived reactive oxygen species and the activation of NF-κB. Oncogene 18:747-757.
12. Floor E, Wetzel MG (1998) Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J Neurochem 70:268-275.
13. Fukuhara Y, Takeshima T, Kashiwaya Y, Shimoda K, Ishitani R, Nakashima K (2001) GAPDH knockdown rescues mesencephalic dopaminergic neurons from MPP+-induced apoptosis. NeuroReport 12:2049-2052.
14. Giasson BI, Lee VM (2000) A new link between pesticides and Parkinson's disease. Nat Neurosci 3:1227-1228.
15. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VM (2000) Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions. Science 290:985-989.
16. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Richardson RJ (1998) The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 50:1346-1350.
17. Hartmann A, Hunot S, Michel PP, Muriel MP, Vyas S, Faucheux BA, Mouatt-Prigent A, Turmel H, Srinivasan A, Ruberg M, Evan GI, Agid Y, Hirsch EC (2000) Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci USA 97:2875-2880.
18. Hasegawa E, Takeshige K, Oishi T, Murai Y, Minakami S (1990) 1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. Biochem Biophys Res Commun 170:1049-1055.
19. Hashimoto M, Takeda A, Hsu LJ, Takenouchi T, Masliah E (1999) Role of cytochrome c as a stimulator of α-synuclein aggregation in Lewy body disease. J Biol Chem 274:28849-28852.
20. Hensley K, Pye QN, Maidt ML, Stewart CA, Robinson KA, Jaffrey F, Floyd RA (1998) Interaction of α-phenyl-N-tert-butyl nitrone and alternative electron acceptors with complex I indicates a substrate reduction site upstream from the rotenone binding site. J Neurochem 71:2549-2557.
21. Hsu LJ, Sagara Y, Arroyo A, Rockenstein E, Sisk A, Mallory M, Wong J, Takenouchi T, Hashimoto M, Masliah E (2000) α-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol 157:401-410.
22. Jenner P (1998) Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov Disord 13:24-34.
23. Jiang D, Jha N, Boonplueang R, Andersen JK (2001) Caspase 3 inhibition attenuates hydrogen peroxide-induced DNA fragmentation but not cell death in neuronal PC12 cells. J Neurochem 76:1745-1755.
24. Kanda S, Bishop JF, Eglitis MA, Yang Y, Mouradian MM (2000) Enhanced vulnerability to oxidative stress by α-synuclein mutations and C-terminal truncation. Neuroscience 97:279-284.
25. King TD, Bijur GN, Jope RS (2001) Caspase-3 activation induced by inhibition of mitochondrial complex I is facilitated by glycogen synthase kinase-3β and attenuated by lithium. Brain Res 919:106-114.
26. Ko L, Mehta ND, Farrer M, Easson C, Hussey J, Yen S, Hardy J, Yen SH (2000) Sensitization of neuronal cells to oxidative stress with mutated human α-synuclein. J Neurochem 75:2546-2554.
27. Kowall NW, Hantraye P, Brouillet E, Beal MF, McKee AC, Ferrante RJ (2000) MPTP induces α-synuclein aggregation in the substantia nigra of baboons. NeuroReport 11:211-213.
28. Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:979-980.
29. Lee HJ, Choi C, Lee SJ (2002a) Membrane-bound α-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J Biol Chem 277:671-678.
30. Lee HJ, Shin SY, Choi C, Lee YH, Lee SJ (2002b) Formation and removal of α-synuclein aggregates in cells exposed to mitochondrial inhibitors. J Biol Chem 277:5411-5417.
31. Leist M, Single B, Naumann H, Fava E, Simon B, Kuhnle S, Nicotera P (1999) Inhibition of mitochondrial ATP generation by nitric oxide switches apoptosis to necrosis. Exp Cell Res 249:396-403.
32. Lotharius J, O'Malley KL (2000) The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation: A novel mechanism of toxicity. J Biol Chem 275:38581-38588.
33. Ma SY, Ciliax BJ, Stebbins G, Jaffar S, Joyce JN, Cochran EJ, Kordower JH, Mash DC, Levey AI. Mufson EJ (1999) Dopamine transporterimmunoreactive neurons decrease with age in the human substantia nigra. J Comp Neurol 409:25-37.
34. McNaught KS, Olanow CW, Halliwell B, Isacson O, Jenner P (2001) Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat Rev Neurosci 2:589-594.
35. Menegon A, Board PG, Blackburn AC, Mellick GD, Le Couteur DG (1998) Parkinson's disease, pesticides, and glutathione transferase polymorphisms. Lancet 352:1344-1346.
36. Mizuno Y, Ohta S, Tanaka M, Takamiya S, Suzuki K, Sato T, Oya H, Ozawa T, Kagawa Y (1989) Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun 163:1450-1455.
37. Nakamura K, Bindokas VP, Marks JD, Wright DA, Frim DM, Miller RJ, Kang UJ (2000) The selective toxicity of 1-methyl-4-phenylpyridinium to dopaminergic neurons: The role of mitochondrial complex I and reactive oxygen species revisited. Mol Pharmacol 58:271-278.
38. Panov AV, Scaduto Jr RC (1996) Substrate specific effects of calcium on metabolism of rat heart mitochondria. Am J Physiol 270:H1398-H1406.
39. Parker Jr WD, Boyson SJ, Parks JK (1989) Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 26:719-723.
40. Pearce RK, Owen A, Daniel S, Jenner P, Marsden CD (1997) Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J Neural Transm 104:661-677.
41. Rideout HJ, Larsen KE, Sulzer D, Stefanis L (2001) Proteasomal inhibition leads to formation of ubiquitin/α-synuclein-immunoreactive inclusions in PC12 cells. J Neurochem 78:899-908.
42. Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD (1989) Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1:1269.
43. Seaton TA, Cooper JM, Schapira AH (1998) Cyclosporin inhibition of apoptosis induced by mitochondrial complex I toxins. Brain Res 809:12-17.
44. Seyfried J, Soldner F, Kunz WS, Schulz JB, Klockgether T, Kovar KA, Wüllner U (2000) Effect of 1-methyl-4-phenylpyridinium on glutathione in rat pheochromocytoma PC 12 cells. Neurochem Int 36:489-497.
45. Sherer TB, Betarbet R, Greenamyre JT (2001a) The rotenone model of Parkinson's disease in vivo: Selective striatal oxidative damage and caspase-3 activation in nigrostriatal neurons. Soc Neurosci Abstr 27:653.2.
46. Sherer TB, Trimmer PA, Borland K, Parks JK, Bennett Jr JP, Tuttle JB (2001b) Chronic reduction in complex I function alters calcium signaling in SH-SY5Y neuroblastoma cells. Brain Res 891:94-105.
47. Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P, Marsden CD (1994) Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36:348-355.
48. Souza JM, Giasson BI, Chen Q, Lee VM, Ischiropoulos H (2000) Dityrosine cross-linking promotes formation of stable α-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J Biol Chem 275:18344-18349.
49. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) α-synuclein in Lewy bodies. Nature 388:839-840.
50. Stephans S, Miller GW, Levey AI, Greenamyre JT (2002) Acute mitochondrial and chronic toxicological effects of 1-methyl-4-phenylpyridinium in human neuroblastoma cells. Neurotoxicology, in press.
51. Tatton NA (2000) Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp Neurol 166:29-43.
52. Tatton NA, Maclean-Fraser A, Tatton WG, Perl DP, Olanow CW (1998) A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease. Ann Neurol 44:S142-148.
53. Taylor SC, Shaw SM, Peers C (2000) Mitochondrial inhibitors evoke catecholamine release from pheochromocytoma cells. Biochem Biophys Res Commun 273:17-21.
54. Trounce IA, Kim YL, Jun AS, Wallace DC (1996) Assessment of mitochondrial oxidative phosphorylation in patient muscle biopsies, lymphoblasts, and transmitochondrial cell lines. Methods Enzymol 264:484-509.
55. Turrens JF, Boveris A (1980) Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria. Biochem J 191:421-427.
56. Uversky VN, Li J, Fink AL (2001) Pesticides directly accelerate the rate of a-synuclein fibril formation: A possible factor in Parkinson's disease. FEBS Lett 500:105-108.
57. Vila M, Vukosavic S, Jackson-Lewis V, Neystat M, Jakowec M, Przedborski S (2000) α-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J Neurochem 74:721-729.
58. Votyakova TV, Reynolds IJ (2001) ΔΨm-dependent and -independent production of reactive oxygen species by rat brain mitochondria. J Neurochem 79:266-277.
59. Wooten GF (1997) Neurochemistry and neuropharmacology of Parkinson's disease. In: Movement Disorders: Neurologic Principles and Practice (Watts RL, Koller WC, eds), pp 153-160. New York: McGraw-Hill.
60. Wüllner U, Kornhuber J, Weller M, Schulz JB, Loschmann PA, Riederer P, Klockgether T (1999) Cell death and apoptosis regulating proteins in Parkinson's disease: A cautionary note. Acta Neuropathol (Berl) 97:408-412.
61. Zhang JG, Tirmenstein MA, Nicholls-Grzemski FA, Fariss MW (2001) Mitochondrial electron transport inhibitors cause lipid peroxidation-dependent and -independent cell death: Protective role of antioxidants. Arch Biochem Biophys 393:87-96.
62. Zhuang S, Demirs JT, Kochevar IE (2001) Protein kinase C inhibits singlet oxygen-induced apoptosis by decreasing caspase-8 activation. Oncogene 20:6764-6776.